Your browser doesn't support javascript.
loading
Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: The SALT-HF trial.
Cobo Marcos, Marta; de la Espriella, Rafael; Comín-Colet, Josep; Zegrí-Reiriz, Isabel; Rubio Gracia, Jorge; Morales-Rull, Jose Luis; Llàcer, Pau; Díez-Villanueva, Pablo; Jiménez-Marrero, Santiago; de Juan Bagudá, Javier; Ortiz Cortés, Carolina; Restrepo-Córdoba, Maria Alejandra; Goirigolzarri-Artaza, Josebe; García-Pinilla, Jose Manuel; Barrios, Elvira; Del Prado Díaz, Susana; Montero Hernández, Esther; Sanchez-Marteles, Marta; Núñez, Julio.
Afiliação
  • Cobo Marcos M; Department of Cardiology, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • de la Espriella R; Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain.
  • Comín-Colet J; Department of Cardiology, Hospital Clínico Universitario de Valencia (INCLIVA), University of Valencia, Valencia, Spain.
  • Zegrí-Reiriz I; Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain.
  • Rubio Gracia J; Department of Cardiology, Hospital Universitario de Bellvitge, IDIBELL, Barcelona, Spain.
  • Morales-Rull JL; Department of Cardiology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
  • Llàcer P; Department of Internal Medicine, Hospital Universitario Lozano Blesa, University of Zaragoza, Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
  • Díez-Villanueva P; Department of Internal Medicine, Hospital Universitario Arnau de Vilanova. Heart Failure Unit, Lleida Health Region. Institut de Recerca Biomèdica de Lleida (IRBLleida), Lleida, Spain.
  • Jiménez-Marrero S; Department of Internal Medicine, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain.
  • de Juan Bagudá J; Department of Medicine and Medical Specialties, Facultad de Medicina y Ciencias de la Salud, Universidad de Alcalá, Madrid, Spain.
  • Ortiz Cortés C; Department of Cardiology, Hospital Universitario de la Princesa, Madrid, Spain.
  • Restrepo-Córdoba MA; Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain.
  • Goirigolzarri-Artaza J; Department of Cardiology, Hospital Universitario de Bellvitge, IDIBELL, Barcelona, Spain.
  • García-Pinilla JM; Centro de Investigación Biomédica en Red (CIBER Cardiovascular), Madrid, Spain.
  • Barrios E; Department of Cardiology, University Hospital 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (Imas12), Madrid, Spain.
  • Del Prado Díaz S; Department of Medicine, Faculty of Biomedical and Health Science, Universidad Europea de Madrid, Madrid, Spain.
  • Montero Hernández E; Department of Cardiology, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain.
  • Sanchez-Marteles M; Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Núñez J; Department of Cardiology, Hospital Universitario Clínico San Carlos, Madrid, Spain.
Eur J Heart Fail ; 26(10): 2118-2128, 2024 Oct.
Article em En | MEDLINE | ID: mdl-39056478
ABSTRACT

AIMS:

Combination of hypertonic saline solution (HSS) with intravenous loop diuretics has been suggested to improve diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this approach in the ambulatory setting remain unexplored. METHODS AND

RESULTS:

In this multicentre, double-blind, randomized study, we allocated ambulatory patients with worsening heart failure (WHF) to a 1-h infusion of intravenous furosemide (ivFurosemide)-HSS versus ivFurosemide. The primary endpoint was the volume of diuresis at 3 h. Secondary endpoints included 3-h natriuresis and weight variation, 7-day congestion data, kidney function and electrolytes, and 30-day clinical events. Overall, 167 participants (median age 81 years, 30.5% female) were randomized across 13 sites between December 2020 and March 2023. There were no differences in 3-h diuresis between treatments (ivFurosemide-HSS 1099 ml vs. ivFurosemide 1103 ml, p = 0.963), 3-h natriuresis (∆ +2.642 mEq/L, p = 0.559), or 3-h weight (∆ +0.012 kg, p = 0.920). Patients in the ivFurosemide-HSS arm experienced significant weight decrease at 7 days (Δ -0.586 kg, p = 0.048). There were no between-treatment differences in clinical congestion score, biomarkers, inferior vena cava diameter, or the presence of lung ultrasound B-lines. At 30 days, 26.5% of the patients in the ivFurosemide-HSS group versus 33.3% in the ivFurosemide group experienced WHF (hazard ratio 0.76, p = 0.330). The incidence of death from any cause or HF hospitalization was 6% of patients in the ivFurosemide-HSS group and 8.3% of patients in the ivFurosemide group (hazard ratio 0.69, p = 0.521). The incidence of worsening kidney function or metabolic derangements was not significantly different in the two arms.

CONCLUSIONS:

A single infusion of ivFurosemide-HSS did not improve 3-h diuresis or congestion parameters in patients with ambulatory WHF. This therapy showed an appropriate safety profile.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Furosemida / Insuficiência Cardíaca Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Furosemida / Insuficiência Cardíaca Limite: Aged / Aged80 / Female / Humans / Male Idioma: En Ano de publicação: 2024 Tipo de documento: Article